How we do R&D
Over the past few years we have continuously improved the organisational and technological framework for cooperation between our Pharmaceuticals and Diagnostics Divisions. Although they have different Research & Development (R&D) processes, the two divisions can share research facilities, technologies and discoveries when working together on internal projects.
This is a unique advantage that sets Roche apart from other companies. Diagnostic tools are finding increasing use in pharmaceutical research. Most importantly, close cooperation is the basis for the successful implementation of our personalised healthcare strategy.
Three Pharma R&D units
To ensure a strong flow of suitable candidate molecules into its development pipeline, Roche has built a unique innovation network of independent Pharma research and development centers.
Pharma Research and Early Development (pRED), Genentech Research and Early Development (gRED) as well as Chugai in Japan operate independently within the group. Together with more than 150 partner organisations worldwide this network promotes a diversity of research approaches, as well as enabling access to new technologies and promising drug candidates.
Roche Pharma Research and Early Development (pRED)
Genentech Research and Early Development (gRED)
Chugai Pharmaceuticals, a member of the Roche Group
R&D in Six Diagnostics Business Areas
A healthcare pioneer and the industry’s global leader in in-vitro diagnostics, the Diagnostics Division pushes boundaries and challenges the status quo to redefine what’s possible. Our commitment to research and development means we can bring to the market integrated solutions in diagnostic testing, laboratory efficiency, healthcare digitalisation and decision support tools and software. Our products deliver increasingly precise information to help save lives, prevent or control the risk of infection and monitor treatment effectiveness.
The Roche Diagnostics Business Areas include Centralised and Point of Care Solutions (CPS), Molecular Diagnostics, Tissue Diagnostics, Sequencing, Diagnostics Information Solutions (DIS), and Diabetes Care. We have R&D facilities in the United States, Austria, Germany, Poland, Switzerland, South Africa and China.
Comprehensive solutions to meet your molecular testing needs
Molecular Diagnostics develops innovative solutions for oncology, infectious diseases, and blood screening so clinicians can improve care for patients.more
Clinical decision support helps turn insights into action
Our goal in DIS is to redefine how data drives patient care and R&D to help ensure the right treatment reaches the individual patient at the right time.more
Staining and instrument systems for testing automation
Providing staining and instrument systems that automate and optimise the tissue diagnostic process for faster, more standardised answers.more
Roche Diabetes Care
We believe that integrated Personalised Diabetes Management is key in helping people with diabetes and those at risk to experience true relief.more
Making next-generation sequencing simple and accessible
Innovating next-generation sequencing solutions that enable a deeper understanding of genetic mutations and inherited diseases.more